Oct 14, 2009 - Pfizer Inc today announced that it has entered into an agreement with two subsidiaries of Mylan Inc. relating to a generic version of Vfend (voriconazole), an antifungal agent. The agreement is limited to the tablet form of Vfend and does not cover Pfizer's Vfend products for intravenous use or oral suspension.
The details can be read here.
No comments:
Post a Comment